Letter to the Editor
Genetic alterations of the mixed-lineage leukemia (MLL) gene are commonly implicated in the development of acute leukemias. In acute myeloid leukemia (AML) a partial tandem duplication (PTD) of MLL occurs in about 5-11% (1) (2) (3) (4) of patients and has been linked to poor treatment outcome (1, 5) . Although recent studies show that MLL-PTD does not have a prognostic impact in CN-AML patients treated with intensive therapy (2, 3) many patients still succumb to their disease (2, 3, (5) (6) (7) , and the course of disease for patients not eligible for intensive chemotherapy is even more dismal. Thus, novel and innovative treatment approaches are needed. In acute leukemias, the MLL gene is also commonly affected by chromosomal rearrangements. Several MLL-rearranged leukemias were recently shown to be dependent on the only known histone 3 lysine 79 (H3K79) methyltransferase DOT1L (8, 9) . Genetic deletion of DOT1L impairs initiation and maintenance of MLL-rearranged leukemias in mouse models (8) (9) (10) (11) (12) and pharmacological inhibition of DOT1L with the specific small molecules EPZ004777 or EPZ-5676 selectively kills MLL-rearranged leukemia cells in vitro (13) and in vivo (14) . Furthermore, DOT1L inhibition leads to a reversal of a characteristic gene expression signature, including downregulation of HOXAcluster genes in MLL-rearranged leukemias (8) (9) (10) . Based on these preclinical findings EPZ-5676 is currently under investigation in a clinical phase-1 trial (NCT01684150). In the current study we assessed whether MLL-PTD positive leukemias that share critical biological features with MLL-rearranged leukemias, such as high expression of HOXA-cluster genes, similarly require DOT1L.
To investigate the effects of pharmacological DOT1L inhibition on cell growth of MLL-PTD positive leukemias, we first treated two human MLL-PTD containing leukemia cell lines, EOL-1 and KOPM-88, with increasing doses of EPZ004777. MOLM-13 and HL-60 were also treated as positive and negative controls, respectively and cell numbers were analyzed over a 14-day period.
DOT1L inhibition reduced the cell number as compared to control for both MLL- In order to determine the effects of DOT1L-inhibition on gene expression, Affymetrix GeneChip Human Genome U133 Plus 2.0 Arrays were performed in EOL-1 cells. HOXA-cluster genes were found among the genes most significantly downregulated after 7 days exposure to EPZ004777 compared to DMSO vehicle control ( Figure 2C ; Supplemental Table T1 ). In fact, HOXA10 was the second most significantly downregulated gene ( Figure 2C ; Supplemental Table T1 ).
Quantitative PCR of HOXA9 and HOXA10 was used to validate the results from gene expression arrays and also revealed similar downregulation of these genes in KOPM-88 cells after 7 days of DOT1L-inhibition (data not shown). The initial rationale for therapeutic targeting of DOT1L came from studies on MLL-rearranged leukemias (9) . In these leukemias, several fusion partners such as AF9, ENL, and AF10, which normally interact with DOT1L, lead to dysregulation of DOT1L and elevated H3K79me2 at MLL-fusion target genes (9, 15) . This ultimately results in the activation of MLL-fusion driven transcriptional programs and thus leukemogenesis (8, 9, 13) . In MLL-PTD positive leukemia, there is no evidence that the mutant MLL protein interacts directly with DOT1L.
However, we observe a response pattern to the DOT1L inhibitor that is in many
ways similar to what has been described for MLL-rearranged leukemias including downregulation of HOXA-cluster and other MLL target genes followed by cell differentiation, apoptosis and cell death. Our data therefore support the hypothesis of an alternative mechanism by which DOT1L is involved in the development of MLL-PTD positive leukemia. Future studies are required to elucidate the exact mechanism by which DOT1L might interact with the MLL-PTD protein and how it specifically contributes to MLL target gene activation. From a clinical perspective, the findings presented here have profound implications.
MLL-PTD is the most common type of MLL alteration in adult AML (1) . Although the status of MLL-PTD as an independent prognostic marker has recently been challenged in multivariate analyses, long-term survival rates are unsatisfactory, ranging between 15% in elderly and 50% in young adult patients (2, 3) . Targeting DOT1L is a highly specific and innovative approach to therapeutically address the epigenetic abnormalities found in MLL-rearranged leukemias. Our data provide a rationale to extend this approach to the patient population carrying a MLL-PTD. Due to the compound's modest toxicity profile estimated from preclinical data (13, 14) , this drug might be of particular value for the increasing population of elderly AML and MDS patients with co-morbid conditions that are not eligible for intensive chemotherapy. Further studies will shed light on the exact mechanism by which DOT1L ultimately contributes to MLL-PTD leukemogenesis. 
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Western blotting
Histones were quantified using the BCA protein quantification kit (23227, Thermo Scientific/Pierce, Rockford, IL, USA) and 1.5 µg of histones was used. Western blotting was performed using a 10 % Bis-Tris Gel with MES Running Buffer 
Chromatin IP-sequencing (ChIP-Seq) and analysis (detailed protocol)
Crosslinking was performed with 1% formalin, the cells were lysed in SDS buffer, For EOL-1, eluted DNA fragments were subjected to sequencing using HiSeq2000 platform. Sequence reads were aligned to human genome assembly hg19 using Bowtie(1). Genome wide ChIP-Seq data was visualized using the integrated genome viewer (IGV) version 2.1. Reads that aligned to multiple loci in the genome were discarded. The ChIP-seq signal was quantified as total number of reads per million in the region 1 Kb upstream of transcription start site (TSS) to 2Kb downstream of TSS for H3K79me2. An empirical background distribution model of reads was constructed to find the significance level of signal at a gene.
ChIP sequencing data will be deposited at the NCBI gene expression omnibus portal (accession number pending).
Gene expression analysis quantitative PCR
Total RNA was isolated using the RNeasy Mini Kit (74104, Qiagen, Ambion, Inc, Austin, TX, USA) and hybridized to Affymetrix GeneChip Human Genome U133 Plus 2.0 Array in accordance with the manufacturer's recommendations. Data analysis was performed using Gene Pattern v3.6.1
(http://www.broad.mit.edu/tools/software.html) and Gene Set Enrichement Analysis (GSEA) software tools (www.broadinstitute.org/gsea) as previously described(2, 3). Data preprocessing was performed using the following filter settings: Floor: 10; ceiling: 20000; min fold change: 1.2; min delta: 20. For comparisons of gene expression between two groups, the expression levels correlated with a particular class was determined by t-test. To determine the 100 most significantly downregulated genes within the EPZ004777 treated group, genes with a fold-change <1.5 and/or a FDR >0.05 were filtered out. The remaining genes were ranked according to t-statistics (Table T1) .
cDNA was generated using the Tetro cDNA Synthesis Kit (65043, Bioline USA Inc, USA) using oligo-dT primers and quantitative PCR was performed using SYBR Green PCR Master Mix on the ABI 7700 Sequence Detection System (Applied Biosystems). Average Ct values were normalized to the housekeeping gene ACTB.
The following primer sets were used (5'-3'): HOXA9, F:
CACCAGACGAACAGTGAGGA, R: TGGTCAGTAGGCCTTGAGGT; HOXA10, F: CCTACACGAAGCACCAGACA, R: GATCCGGTTTTCTCGATTCA; ACTB, F:
GCACAGAGCCTCGCCTT, R: CCTTGCACATGCCGGAG; and GAPDH, F:
GAAGGTGAAGGTCGGAGT, R: GAAGATGGTGATGGGATTTC.
Gene expression array data were deposited at the NCBI gene expression omnibus portal (accession number pending). ELISA assay and HOXA9 qRT-PCR was performed as previously described(4).
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